Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting

INTRODUCTION: Subcutaneous (SC) drug administration, such as the Herceptin® in an oncology day hospital reduces the administration time of trastuzumab. In the context of combination therapy administration, this time-saving may be called into question. The challenge posed by the deployment of much le...

Descripción completa

Detalles Bibliográficos
Autores principales: Barat, Eric C., Arrii, Marianne L.E., Soubieux-Bourbon, Annaelle, Daouphars, Mikaël, Varin, Rémi, Tilleul, Patrick R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587754/
https://www.ncbi.nlm.nih.gov/pubmed/37857129
http://dx.doi.org/10.1016/j.breast.2023.103588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587754/
https://www.ncbi.nlm.nih.gov/pubmed/37857129
http://dx.doi.org/10.1016/j.breast.2023.103588

Ejemplares similares